The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II open‐label study with atezolizumab (atezo) in combination with bevacizumab (bev) in patients (pts) with advanced chemotherapy-resistant colorectal cancer (CRC) and MSI‐like molecular signature: The MoTriColor Consortium CT3 study.
 
Elena Elez
Honoraria - Amgen; Array BioPharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; Janssen; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Roche; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim Spain (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Genentech (Inst); Gercor (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); Taiho Pharmaceutical (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Agenus; AstraZeneca; Bayer; Bristol-Myers Squibb; CheckmAb; Daiichi Sankyo; GlaxoSmithKline; Merck; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Seagen; T-One Therapeutics
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Andrea Sartore-Bianchi
Honoraria - Guardant Health
Consulting or Advisory Role - Amgen; Bayer; Novartis; Pierre Fabre; SERVIER
 
Fortunato Ciardiello
Consulting or Advisory Role - Amgen; Bayer; Merck KGaA; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst); SERVIER (Inst); Symphogen (Inst)
 
Erika Martinelli
Consulting or Advisory Role - Amgen; AstraZeneca; Merck KGaA; Pierre Fabre; Roche; SERVIER
Travel, Accommodations, Expenses - AstraZeneca; Pierre Fabre
 
Sabine Tejpar
Honoraria - Merck Serono; Regeneron
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Merck Serono; Regeneron; Roche/Genentech
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Serono; Roche; Sanofi
 
Neeltje Steeghs
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene; Ellipses Pharma (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Incyte; Incyte (Inst)
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); Ascendis Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CellCentric (Inst); Cogent Biosciences (Inst); Crescendo Biologics (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); IDRx (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Kling Biotherapeutics (Inst); Lixte Biotechnology (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Molecular Partners (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Zentalis (Inst)
 
Andres Cervantes
Consulting or Advisory Role - Amgen (Inst); Foundation Medicine (Inst); Merck Serono (Inst); Roche (Inst); Transgene (Inst)
Research Funding - Actuate Therapeutics (Inst); Adaptimmune (Inst); Amcure (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Spain (Inst); Bayer (Inst); BeiGene (Inst); BMSi (Inst); FibroGen (Inst); Genentech (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); SERVIER (Inst); Sierra Oncology (Inst); Takeda (Inst)
Other Relationship - Annals of Oncology; Cancer Treatment Reviews; ESMO Open
 
Ramon Salazar
Leadership - Sace Medhealth; SaceMedhealth (I)
Consulting or Advisory Role - Genzyme; GlaxoSmithKline; WntResearch
Research Funding - WntResearch
Expert Testimony - Esteve; SERVIER
Travel, Accommodations, Expenses - Esteve
 
Javier Ros Montañá
Honoraria - Amgen
Speakers' Bureau - Sanofi
Travel, Accommodations, Expenses - Amgen; Amgen; Merck; Pierre Fabre; SERVIER
 
Bieke Wilmsen
No Relationships to Disclose
 
Sanne Huijberts
No Relationships to Disclose
 
Susana Roselló-Keränen
Research Funding - GlaxoSmithKline (Inst); Inspirna (Inst); Janssen Oncology (Inst); Mirati Therapeutics (Inst); Nouscom (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Cristina Santos
Travel, Accommodations, Expenses - Amgen; Merck KGaA; MSD Oncology
 
Eduardo García-Galea
No Relationships to Disclose
 
Gaetan de Schaetzen
No Relationships to Disclose
 
Victor Moreno Aguado
Stock and Other Ownership Interests - ANILING
 
Rene Bernards
Employment - Agendia
Stock and Other Ownership Interests - Agendia
 
Rodrigo Dienstmann
Employment - Oncoclínicas
Stock and Other Ownership Interests - Trialing Health
Consulting or Advisory Role - Boehringer Ingelheim; Foundation Medicine; Roche
Speakers' Bureau - Amgen; AstraZeneca; GlaxoSmithKline; Ipsen; Janssen Oncology; Libbs; Lilly; MSD Oncology; Roche; Sanofi; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck; Novartis (Inst)
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Alentis Therapeutics; AstraZeneca; AVEO; Boehringer Ingelheim; Cardiff Oncology; CARsgen Therapeutics; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; hC Bioscience Inc; Ikena Oncology; Immodulon Therapeutics; Inspirna; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo
Other Relationship - Imedex/HMP; Medscape; Peerview; Physicans' Education Resource